Correspondence 0001493152-24-005996 from Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc.
Date: Feb. 13, 2024 · CIK: 0001708599 · Accession: 0001493152-24-005996
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275536
Letter
AgeX Therapeutics, Inc.
Marina Village Parkway
Suite
Alameda, California 94501
(510) 671-8370
February 13, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
F Street, N.E.
Washington, DC 20549
Attn: Cindy Polynice
Laura Crotty
Jenn Do
Kevin Vaughn
Re: AgeX Therapeutics, Inc.
Registration Statement on Form S-4/S-1 (File No. 333-275536)
Ladies and Gentleman:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Act”), AgeX Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above-referenced Registration Statement on Form S-4/S-1 filed by the Company (the “Registration Statement”) be accelerated to 3:30 p.m., Eastern Standard Time, on February 13, 2024 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Harrison Tucker at (346) 718-6643, or in his absence, Chris W. Trester at (650) 849-5212. We also respectfully request that a copy of the written order from the U.S. Securities and Exchange Commission verifying the effective time of such Registration Statement be sent to Gibson, Dunn & Crutcher LLP, attention: Harrison Tucker, via email at HTucker@gibsondunn.com.
[Signature page follows]
Very
truly yours,
AgeX
Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
AgeX
Therapeutics, Inc.
1101
Marina Village Parkway
Suite
201
Alameda,
California 94501
(510)
671-8370
February
13, 2024
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, N.E.
Washington,
DC 20549
Attn:
Cindy
Polynice
Laura
Crotty
Jenn
Do
Kevin
Vaughn
Re:
AgeX
Therapeutics, Inc.
Registration Statement on Form S-4/S-1 (File No. 333-275536)
Ladies
and Gentleman:
Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Act”), AgeX Therapeutics, Inc., a Delaware corporation
(the “Company”), hereby respectfully requests that the effective time of the above-referenced Registration Statement on Form
S-4/S-1 filed by the Company (the “Registration Statement”) be accelerated to 3:30 p.m., Eastern Standard Time, on February
13, 2024 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone
that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges
that it is aware of its obligations under the Act.
Once
the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling
Harrison Tucker at (346) 718-6643, or in his absence, Chris W. Trester at (650) 849-5212. We also respectfully request that a copy of
the written order from the U.S. Securities and Exchange Commission verifying the effective time of such Registration Statement be sent
to Gibson, Dunn & Crutcher LLP, attention: Harrison Tucker, via email at HTucker@gibsondunn.com.
[Signature
page follows]
Very
truly yours,
AgeX
Therapeutics, Inc.
By:
/s/
Andrea E. Park
Name:
Andrea
E. Park
Title:
Chief
Financial Officer
cc:
Robert
Phillips, Gibson, Dunn & Crutcher LLP
Harrison
Tucker, Gibson, Dunn & Crutcher LLP
Chris
W. Trester, Gibson, Dunn & Crutcher LLP
Scott
Ludwig, Bradley Arant Boult Cummings LLP
Stephen
Hinton, Bradley Arant Boult Cummings LLP
[Signature Page to Acceleration Request]